Results 311 to 320 of about 22,605,370 (372)
Interpretable Multimodal Fusion Model Enhances Postoperative Recurrence Prediction in Gastric Cancer
An interpretable multimodal fusion model (RSA) integrating clinical, radiomic, and pathomic features is developed and validated to predict early postoperative recurrence in gastric cancer. The RSA model demonstrates superior predictive performance and holds potential for guiding adjuvant chemotherapy decisions and improving individualized patient ...
Ping'an Ding +16 more
wiley +1 more source
In this study, the expression and function of LCN2 in GC is aimed to investigate and elucidate the mechanisms by which the LCN2‐dependent positive‐feedback loop between GC cells and TAMs drives lymphangiogenesis and lymphatic metastasis. These findings suggest that LCN2 may serve as a potential prognostic biomarker and therapeutic target in GC ...
Zhixin Huang +15 more
wiley +1 more source
Single‐Cell RNA Sequencing of Thyroid Tissues Reveals Pathogenesis of Graves' Disease
Using single‐cell RNA sequencing and TCR profiling, this study constructed an immune cell atlas in thyroid tissue of Graves’ disease (GD), revealing dominant IFN‐γ‐secreting CD4+ T cells, expanded Tph and CD11c+ B cells, and enriched T/NK cells. Notably, GD thyroid follicular cells (TFCs) activated γδ T cells, which recruited cDC1 cells, suggesting a ...
Xiaoyi Zhou +18 more
wiley +1 more source
Comparative cochlear transcriptomics of noise‐exposed bats (Miniopterus fuliginosus) and mice reveals bat‐specific protection mechanisms for noise‐induced hearing loss (NIHL), identifying Hras as a key hub regulator. Functional studies in mice show hair‐cell‐specific Hras overexpression significantly reduced hair‐cell damage and NIHL by activating the ...
Peng Chen +9 more
wiley +1 more source
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun +23 more
wiley +1 more source

